Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

L Degenhardt, B Clark, G Macpherson… - The Lancet …, 2023 - thelancet.com
Background Opioid dependence is associated with substantial health and social burdens,
and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for …

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

RP Mattick, C Breen, J Kimber… - Cochrane database of …, 2014 - cochranelibrary.com
Background Buprenorphine maintenance treatment has been evaluated in randomised
controlled trials against placebo medication, and separately as an alternative to methadone …

Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic …

D Jutras-Aswad, B Le Foll, K Ahamad… - American Journal of …, 2022 - Am Psychiatric Assoc
Objective: Extensive exposure to prescription-type opioids has resulted in major harm
worldwide, calling for better-adapted approaches to opioid agonist therapy. The authors …

[HTML][HTML] Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials

J Klimas, MA Hamilton, L Gorfinkel, A Adam… - Systematic reviews, 2021 - Springer
Background Although oral opioid agonist therapies (OATs), buprenorphine and methadone,
are effective first-line treatments, OAT remains largely underutilized due to low retention …

Buprenorphine treatment of opioid‐dependent pregnant women: a comprehensive review

HE Jones, SH Heil, A Baewert, AM Arria… - …, 2012 - Wiley Online Library
Aims This paper reviews the published literature regarding outcomes following maternal
treatment with buprenorphine in five areas: maternal efficacy, fetal effects, neonatal effects …

[HTML][HTML] Relative effectiveness of medications for opioid-related disorders: a systematic review and network meta-analysis of randomized controlled trials

J Lim, I Farhat, A Douros, D Panagiotoglou - PLoS One, 2022 - journals.plos.org
Introduction Several pharmacotherapeutic interventions are available for maintenance
treatment for opioid-related disorders. However, previous meta-analyses have been limited …

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence

JS Orman, GM Keating - Drugs, 2009 - Springer
Buprenorphine/naloxone (Suboxone®) comprises the partial μ-opioid receptor agonist
buprenorphine in combination with the opioid antagonist naloxone in a 4: 1 ratio. When …

Buprenorphine–naloxone therapy in pain management

KY Chen, L Chen, J Mao - Anesthesiology, 2014 - pubs.asahq.org
Buprenorphine–naloxone (bup/nal in 4: 1 ratio; Suboxone®; Reckitt Benckiser
Pharmaceuticals Incorporation, Richmond, VA) is approved by the Food and Drug …

Evidence-based pharmacological treatment of substance use disorders and pathological gambling

W Van den Brink - Current drug abuse reviews, 2012 - ingentaconnect.com
This review summarizes our current knowledge of the pharmacological treatment of
substance use disorders and pathological gambling using data mainly from randomized …

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid …

M Soyka, HR Kranzler, W van den Brink… - The world journal of …, 2011 - Taylor & Francis
Objectives. To develop evidence-based practice guidelines for the pharmacological
treatment of opioid abuse and dependence. Methods. An international task force of the …